George Fotakopoulos, Vasiliki Epameinondas Georgakopoulou, Demetrios A Spandidos, Petros Papalexis, Efthalia Angelopoulou, Aikaterini Aravantinou-Fatorou, Nikolaos Trakas, Ilias Trakas, Alexandros G Brotis
{"title":"Role of miR‑200 family in brain metastases: A systematic review.","authors":"George Fotakopoulos, Vasiliki Epameinondas Georgakopoulou, Demetrios A Spandidos, Petros Papalexis, Efthalia Angelopoulou, Aikaterini Aravantinou-Fatorou, Nikolaos Trakas, Ilias Trakas, Alexandros G Brotis","doi":"10.3892/mco.2023.2611","DOIUrl":null,"url":null,"abstract":"<p><p>Brain metastasis (BM) represents the single most severe neurological complication of systemic cancer. The prognosis of patients with BM is poor, irrespective of the implemented treatment. The present study performed a systematic review of the literature using three online databases (PubMed, Scopus and Web of Science). Recently, a number of small RNA molecules, the microRNAs (miRNAs/miRs), have attracted increasing scientific attention. Members of the miR-200 family, which includes five miRNAs (miR-141, miR-200a, miR-200b, miR-200c and miR-429) appear to play pivotal roles in cancer initiation and metastasis. Indeed, a systematic review of the pertinent literature revealed that miR-200 family members regulate the brain metastatic cascade, particularly by modulating epithelial-to-mesenchymal transition. That holds true for the major representatives of BM, including lung and breast cancer, as well as for other less frequent secondary lesions originating from melanoma and the gastrointestinal tract. Therefore, the miRNAs may serve as potential diagnostic and/or prognostic markers, and under specific circumstances, as invaluable therapeutic targets. However, the available clinical evidence is relatively limited. A number of studies have suggested that the miR-200 family members are accurate prognostic markers of survival and resistance to chemotherapy in patients with breast cancer. Similarly, they may prove helpful in differentiating a metastatic lesion from a malignant glioma, or a hemangioblastoma from a renal cell carcinoma in patients with von Hippel Lindau syndrome, based on a cerebrospinal fluid sample. However, currently, there is no known therapeutic role for miR-200 family members in the setting of BM.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/ec/mco-18-03-02611.PMC9926042.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2023.2611","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Brain metastasis (BM) represents the single most severe neurological complication of systemic cancer. The prognosis of patients with BM is poor, irrespective of the implemented treatment. The present study performed a systematic review of the literature using three online databases (PubMed, Scopus and Web of Science). Recently, a number of small RNA molecules, the microRNAs (miRNAs/miRs), have attracted increasing scientific attention. Members of the miR-200 family, which includes five miRNAs (miR-141, miR-200a, miR-200b, miR-200c and miR-429) appear to play pivotal roles in cancer initiation and metastasis. Indeed, a systematic review of the pertinent literature revealed that miR-200 family members regulate the brain metastatic cascade, particularly by modulating epithelial-to-mesenchymal transition. That holds true for the major representatives of BM, including lung and breast cancer, as well as for other less frequent secondary lesions originating from melanoma and the gastrointestinal tract. Therefore, the miRNAs may serve as potential diagnostic and/or prognostic markers, and under specific circumstances, as invaluable therapeutic targets. However, the available clinical evidence is relatively limited. A number of studies have suggested that the miR-200 family members are accurate prognostic markers of survival and resistance to chemotherapy in patients with breast cancer. Similarly, they may prove helpful in differentiating a metastatic lesion from a malignant glioma, or a hemangioblastoma from a renal cell carcinoma in patients with von Hippel Lindau syndrome, based on a cerebrospinal fluid sample. However, currently, there is no known therapeutic role for miR-200 family members in the setting of BM.
脑转移(BM)是系统性癌症最严重的神经系统并发症。无论实施何种治疗,BM患者的预后都很差。本研究使用三个在线数据库(PubMed、Scopus和Web of Science)对文献进行了系统的综述。近年来,一些小RNA分子,即microRNAs (miRNAs/miRs),引起了越来越多的科学关注。miR-200家族的成员,包括5个mirna (miR-141、miR-200a、miR-200b、miR-200c和miR-429),似乎在癌症的发生和转移中发挥关键作用。事实上,对相关文献的系统回顾显示,miR-200家族成员调节脑转移级联反应,特别是通过调节上皮细胞到间质细胞的转变。这适用于BM的主要代表,包括肺癌和乳腺癌,以及其他不太常见的源于黑色素瘤和胃肠道的继发性病变。因此,mirna可以作为潜在的诊断和/或预后标志物,并在特定情况下作为宝贵的治疗靶点。然而,现有的临床证据相对有限。许多研究表明,miR-200家族成员是乳腺癌患者生存和化疗耐药的准确预后标志物。同样,根据脑脊液样本,它们可能有助于区分转移性病变与恶性胶质瘤,或血管母细胞瘤与肾细胞癌。然而,目前还没有发现miR-200家族成员在BM中的治疗作用。